Here's What Key Metrics Tell Us About Conmed (CNMD) Q4 Earnings

For the quarter ended December 2024, Conmed (CNMD) reported revenue of $345.94 million, up 5.8% over the same period last year. EPS came in at $1.34, compared to $1.06 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $341.3 million, representing a surprise of +1.36%. The company delivered an EPS surprise of +11.67%, with the consensus EPS estimate being $1.20.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Conmed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Geographic Revenue- International: $142.60 million versus $149.63 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +4.3% change. Geographic Revenue- Domestic: $203.30 million versus $191.26 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +6.8% change. Net Sales- Orthopedic Surgery: $139 million versus $134.12 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +1.8% change. Net Sales- General Surgery: $206.90 million versus $199.47 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +8.6% change. Net Sales- Single-use Products: $297.30 million versus the two-analyst average estimate of $289.01 million. The reported number represents a year-over-year change of +9.6%. Net Sales- Capital Products: $48.60 million versus the two-analyst average estimate of $51.88 million. The reported number represents a year-over-year change of -12.8%. View all Key Company Metrics for Conmed here>>>Shares of Conmed have returned +6.3% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CONMED Corporation (CNMD): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks